J&J finalizes $25M settlement, laying Remicade antitrust allegations to rest
A Pennsylvania federal judge on Wednesday cemented a $25 million settlement in a class action suit alleging Johnson & Johnson blocked biosimilar competition to its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.